Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

BACKGROUND Vaccines are needed to prevent coronavirus disease 2019 (Covid-19) and to protect persons who are at high risk for complications. The mRNA-1273 vaccine is a lipid nanoparticle–encapsulated mRNA-based vaccine that encodes the prefusion stabilized full-length spike protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes Covid-19. METHODS This phase 3 randomized, observer-blinded, placebo-controlled trial was conducted at 99 centers across the United States. Persons at high risk for SARS-CoV-2 infection or its complications were randomly assigned in a 1:1 ratio to receive two intramuscular injections of mRNA-1273 (100 μg) or placebo 28 days apart. The primary…

• NI
  National Institute of Allergy and Infectious Diseases

  Awards: HVTN Statistics and Data Management Center UM1 AI, HVTN Leadership and Operations Center UM1 AI 68614, IDCRC leadership group 5 UM1 AI148684-03, HVTN Laboratory Center UM1 AI 68618, HPTN Leadership and Operations Center UM1 AI 68619, ACTG Leadership and Operations Center UM1 AI 68636